USA flag logo/image

An Official Website of the United States Government

Drug Discovery from Slow Growing and Rare Microbial Species

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95808
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AI091224
Solicitation Year:
N/A
Solicitation Topic Code:
NIAID
Solicitation Number:
N/A
Small Business Information
NovoBiotic Pharmaceuticals, LLC
767C Concord Avenue Cambridge, MA 02138-1044
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Drug Discovery from Slow Growing and Rare Microbial Species
Agency: HHS
Contract: 1R43AI091224-01
Award Amount: $598,976.00
 

Abstract:

DESCRIPTION (provided by applicant): Multidrug resistant organisms are increasingly prevalent in nosocomial and community settings. Novel antibiotics with new mechanisms of action are needed to combat the impending public health crisis of antibiotic-resist ant pathogens like Staphylococcus aureus, Enterococcus faecium, Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumanii, and Klebsiella pneumoniae, among others. The added threat of bioterrorism with an agent most certainly engineered to be resi stant to currently available antibiotics makes this need particularly acute. The long-term goal of this project is to address this need by developing a pipeline of novel broad spectrum antimicrobial compounds. Most antibiotics in use today have come from n atural products obtained from less than 1% of microbial species cultivable by conventional methods. The remaining 99% of as yet uncultivated species represent essentially an unlimited diversity of microorganisms to discover novel antibiotics. In this Phase I project we aim to access some of these missing species. We will develop a method to isolate slow growing and rare species that until now remained uncultivated and unexplored. It has been conventional but unproven wisdom that these bacteria are unsuite d for a drug discovery pipeline because the rate of their discovery is low, and large scale growth is problematic. Here we present evidence that neither assumption holds, and that in fact, slow growing and rare species can be an excellent resource of antim icrobial discovery. The specific aims for this project are: Aim 1: Develop long-term incubation method to cultivate slower growing and rare cells; Aim 2: Scale up growth of novel species and screen for antimicrobial activity; Aim 3: Investigate the chemica l novelty of the discovered activities. The data in Phase I will demonstrate whether slow growing isolates represent novel species that can be isolated in large numbers and efficiently converted into fast growing cultures and whether these species produce potentially novel antibiotics. The results in Phase I will will inform our cultivation strategy in Phase II, in which we will establish a large-scale drug discovery pipeline sufficient for discovery of novel broad-spectrum antibiotics from a novel pool of microbial diversity. PUBLIC HEALTH RELEVANCE: The threat of increased antibiotic resistance in bacteria urgently requires development of novel antimicrobials. This proposal aims to develop a new pipeline for discovery of antibiotics from novel, prev iously uncultivated microorganisms to combat this impending public health crisis.

Principal Investigator:

Amy Spoering
8579285616
ASPOERING@NOVOBIOTIC.COM

Business Contact:

Amy Spoering
asalzman@novobiotic.com
Small Business Information at Submission:

NOVOBIOTIC PHARMACEUTICALS, LLC
NOVOBIOTIC PHARMACEUTICALS, LLC 767C CONCORD AVE CAMBRIDGE, MA -

EIN/Tax ID: 181063608
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No